A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 274 participants.

Also called NCT06323161

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 274 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT06323161
Other papers using this trial's data
  • Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study Lancet (London, England), 2026-07-04 DOI, PubMed 42251856

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, China, Japan, Serbia, Slovakia, South Africa (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06323161. Randomized; quadruple masking; primary purpose treatment. Start 2024-03-26 (actual); primary completion 2025-09-09 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin
Acronym
REIMAGINE 3
Intervention (Drug)
Cagrilintide
Intervention (Drug)
Semaglutide
Intervention (Drug)
Placebo
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct06323161
Content hash
2ab7894adfb0ede5afb10e1b316c5553e0e103a5a0c198eccdf8c77ffa329f51